The DASIS Report: Planned
Methadone Treatment for Non-Heroin Opiate Admissions
Highlights
- Methadone
is an opioid agonist medication used to treat heroin and other opiate
addiction. Methadone reduces the craving for heroin and other
opiates by blocking the receptor sites that are affected by heroin or
other opiates.
- Non-heroin
opiates include methadone, codeine, Dilaudid, morphine, Demerol, opium,
oxycodone, and any other drug with morphine-like effects.
- Based
on SAMHSA's 2000 Treatment Episode Data Set (TEDS), admissions with
non-heroin opiates as a primary substance of abuse accounted for 26,900
(10 percent) of the 269,400 opiate admissions. Methadone treatment
was planned for 19 percent of the non-heroin opiate treatment admissions.
- Non-heroin
opiate admissions with planned methadone treatment were almost twice
as likely as admissions with no planned methadone treatment to be self-
or individually referred (81 vs. 43 percent).
- Among
the non-heroin opiate admissions, methadone treatment was planned for
66 percent of Asian/Pacific Islanders, 24 percent of Blacks, 20 percent
of Hispanics, 17 percent of American Indian/Alaska Natives, and 17 percent
of Whites.
Reports
on treatment
Reports
on opiates
Other
topics
Other
OAS publications and services
This OAS
Short Report, The
DASIS Report: Planned Methadone Treatment for Non-Heroin
Opiate Admissions, is based on the Drug
and Alcohol Services Information System (DASIS), the primary
source of national data on substance abuse treatment. DASIS
is conducted by the Office of Applied Studies (OAS)
in the Substance Abuse and Mental Health Services Administration (SAMHSA).
|
